Abstract 154P
Background
The variants of urothelial carcinoma such as micropapillary (MP), plasmacytoid (PC), and lipid cell (LC) carry a very poor prognosis. High progression speed and resistance to chemotherapy are considered to be part of the reasons for poor prognosis. Accordingly, early diagnosis and early treatment are important to improve prognosis. In this study, we elucidated the cytological diagnostic criteria of these variants, and also investigated whether preoperative urine cytology could diagnose these variants and the possible association between cytological predictability and pathological features.
Methods
Between April 2015 and March 2020, 45 patients were histologically diagnosed as MP, PC, and LP by TURBT in our institution. The experienced cytologists (YW) in our hospital re-evaluated the preoperative urine cytology in these cases to determine whether or not the prediction of the variant histology is possible. The following findings were used as criteria, small papillary cell clumps with strong binding in MP, circular atypical cells similar to plasma cells in PC, and atypical cells similar to lipoblasts with empty cells in LC. Additionally, we analyzed whether histopathological findings such as muscle invasion, tumor size, tumor necrosis, lymphovascular invasion (LVI), CIS, affect the prediction of the variants.
Results
Of 45 cases, MP, PC and LC were 18 (40%), 13 (29%) and 14 (31%) patients, respectively. 3 cases of MP (17%), 5 of PC (38%) and 2 of LC (14%) could be predicted by re-evaluating preoperative urine cytology. In addition, positive preoperative urine cytology (class 4 or higher) was found in 14 cases in MP (78%), 8 cases in PC (62%), and 11 cases in LC (79%), with estimated probabilities of 21%, 62%, and 18%, respectively. Pathological features were not different between the predictable and unpredictable cases: muscle invasion, 90% vs 74% (P = 0.26); median tumor size, 31 mm vs 38 mm (P = 0.37); tumor necrosis, 20% vs 28% (P = 0.64); LVI, 60% vs 45% (P = 0.42); CIS, 40% vs 34% (P = 0.74), respectively.
Conclusions
Although in some cases, atypical cells suggesting UC variants appeared in the urine cytology, this study suggested that the preoperative cytological diagnosis of bladder cancer variants seems to be difficult.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
247TiP - Addition of induction, concurrent and maintenance durvalumab to induction and concurrent chemoradiation vs induction and concurrent chemoradiation for previously untreated locoregionally advanced nasopharyngeal carcinoma: A phase II randomised-controlled trial
Presenter: Victor Lee
Session: Poster viewing 03
248P - The use of complementary medicine in Chinese pediatric patients receiving palliative care: A multi-centre study
Presenter: Chun SIng Lam
Session: Poster viewing 03
249P - Improving quality of life and symptom burden with opioids and adjuncts in lung cancer (IQSOL study)
Presenter: Naren Gokulanathan
Session: Poster viewing 03
250P - An analysis of nutritional and psychological status of patients with advanced cancer
Presenter: Shasha Wang
Session: Poster viewing 03
251P - Is QUAD SHOT palliative cyclical hypo-fractionated radiotherapy in advanced head and neck cancer the way to go? An alternative regimen in low resource countries
Presenter: Ravi Kanodia
Session: Poster viewing 03
252P - Preferred place of death among terminally ill cancer patients: A single centre observational study from India
Presenter: Suhana Sulfiker
Session: Poster viewing 03
253P - Hemostatic radiotherapy for gastric cancer: MRI as an alternative to endoscopy for post-treatment evaluation
Presenter: Osamu Tanaka
Session: Poster viewing 03
254P - Sexual function of cervical cancer survivors: A single center prospective study
Presenter: Dinesh Ravikumar
Session: Poster viewing 03
255P - Volunteers’ role to provide quality palliative care for terminal cancer
Presenter: SAPTAPARNA JANA
Session: Poster viewing 03